NEW YORK--(BUSINESS WIRE)--Diversified Natural Products, Inc. reported results of a new study presented this week at the 58th annual Scientific Sessions of the American College of Cardiology, demonstrating that the addition of HEP-40 (enzymatically hydrolyzed polysaccharide with a molecular weight of 40 kiloDaltons) to statin therapy significantly lowered low-density lipoprotein (LDL) cholesterol and improved lipid profiles in patients who had not reached target LDL levels.
